Literature DB >> 20386298

Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation.

Carlos Fernández-de Larrea, Frederic Cofan, Federico Oppenheimer, Josep Maria Campistol, Gines Escolar, Miguel Lozano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20386298     DOI： 10.1097/TP.0b013e3181ccd80d

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  27 in total

1.  Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome.

Authors:  Carla Nester; Zoe Stewart; David Myers; Jennifer Jetton; Ramesh Nair; Alan Reed; Christie Thomas; Richard Smith; Patrick Brophy
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-26       Impact factor: 8.237

Review 2.  Current treatment of atypical hemolytic uremic syndrome.

Authors:  Bernard S Kaplan; Rebecca L Ruebner; Joann M Spinale; Lawrence Copelovitch
Journal:  Intractable Rare Dis Res       Date:  2014-05

Review 3.  Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.

Authors:  Julien Zuber; Fadi Fakhouri; Lubka T Roumenina; Chantal Loirat; Véronique Frémeaux-Bacchi
Journal:  Nat Rev Nephrol       Date:  2012-10-02       Impact factor: 28.314

4.  Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome.

Authors:  Anne-Laure Lapeyraque; Véronique Frémeaux-Bacchi; Pierre Robitaille
Journal:  Pediatr Nephrol       Date:  2010-12-15       Impact factor: 3.714

5.  Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome.

Authors:  Marcus Weitz; Oliver Amon; Dirk Bassler; Alfred Koenigsrainer; Silvio Nadalin
Journal:  Pediatr Nephrol       Date:  2011-05-10       Impact factor: 3.714

Review 6.  New insights into postrenal transplant hemolytic uremic syndrome.

Authors:  Julien Zuber; Moglie Le Quintrec; Rebecca Sberro-Soussan; Chantal Loirat; Véronique Frémeaux-Bacchi; Christophe Legendre
Journal:  Nat Rev Nephrol       Date:  2010-11-23       Impact factor: 28.314

7.  Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses.

Authors:  Gwenaëlle Sana; Marie-Agnès Dragon-Durey; Marina Charbit; Karim Bouchireb; Caroline Rousset-Rouvière; Etienne Bérard; Rémi Salomon; Véronique Frémeaux-Bacchi; Patrick Niaudet; Olivia Boyer
Journal:  Pediatr Nephrol       Date:  2013-07-19       Impact factor: 3.714

Review 8.  Eculizumab: a review of its use in atypical haemolytic uraemic syndrome.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-12       Impact factor: 9.546

Review 9.  Atypical hemolytic uremic syndrome.

Authors:  Chantal Loirat; Véronique Frémeaux-Bacchi
Journal:  Orphanet J Rare Dis       Date:  2011-09-08       Impact factor: 4.123

10.  Successful treatment of DEAP-HUS with eculizumab.

Authors:  Damien Noone; Aoife Waters; Fred G Pluthero; Denis F Geary; Michael Kirschfink; Peter F Zipfel; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2013-11-20       Impact factor: 3.714
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.